Amendments to the Claims:

Please cancel Claims 1 – 33. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-33 (cancelled)

Claim 34. (new) A process for producing a cell growth media component containing lipoprotein material, wherein the process reduces, eliminates or inactivates a transmissible spongiform encephalopathy agent that is present in the lipoprotein material.

Claim 35. (new) The process of claim 34 wherein the lipoprotein material is contacted with a solution of base at a pH of between 10 and 13 for a sufficient time period to cause prion inactivation in a manner that does not substantially adversely affect the biological activity of the lipoprotein material.

Claim 36. (new) The process of claim 34 wherein the lipoprotein material is contacted with an adsorbant that binds more tightly to a lipoprotein than to a prion to reduce the prions present in the lipoprotein material.

Claim 37. (new) The process of claim 36 wherein the adsorbant is silica.

Claim 38. (new) The process of claim 34 wherein the lipoprotein material consists essentially of HDL.

Claim 39. (new) The process of claim 36, wherein the lipoprotein material is contacted with the solution of base at approximately room temperature.

Claim 40. (new) The process of claim 35, wherein the base is sodium hydroxide.

Claim 41. (new) The process of claim 35, wherein the base is potassium hydroxide.

Claim 42. (new) The process of claim 35, wherein the base is hydroxide ion.

Claim 43. (new) The process of claim 35, wherein the base is an ammonium ion or amine.

Claim 44. (new) The process of claim 35, wherein the base is in a concentration of between 0.1 and 1N solution.

Claim 45. (new) The process of claim 35, wherein the lipoprotein material is contacted with the base for a period of time of from initial contact up to 10 hours.

Claim 46. (new) The process of claim 35, wherein the lipoprotein material is contacted with the base for at least 2 hours.

Claim 47. (new) The process of claim 35, wherein the lipoprotein material is contacted with the base for at least 4 hours.

Claim 48. (new) The process of claim 35, wherein the lipoprotein material is contacted with the base for at least 6 hours.

Claim 49. (new) The process of claim 35 wherein the lipoprotein material is contacted with the base for at least 8 hours.

Claim 50. (new) The process of claim 35, wherein the lipoprotein material is contacted with the base for at least 10 hours.

Claim 51. (new) The process of claim 35, wherein the wherein the lipoprotein material is contacted at a pH of about 12 for about 8 hours.

Claim 52. (new) The process of claim 35, wherein the lipoprotein material is contacted at a temperature between about 16° C and about 24° C.

Claim 53. (new) The process of claim 34, wherein the lipoprotein in the lipoprotein material is at a concentration between 10 and 3,500 mg/dL.

Claim 54. (new) The process of claim 34, wherein the lipoprotein in the lipoprotein material is at a concentration between 50 and 500 mg/dL.

Claim 55. (new) The process of claim 35, further comprising after contacting the lipoprotein material with a solution of base adjusting the pH to a neutral pH using a pH-adjusting agent that does not adversely affect the lipoprotein material.

Claim 56. (new) The process of claim 34, wherein the lipoprotein material comprises lipoprotein material and solvent.

Claim 57. (new) The process of claim 34, wherein the lipoprotein material is substantially pure lipoprotein.

Claim 58. (new) The process of claim 34, wherein the lipoprotein is in a solvent selected from water, saline, and buffer.

Claim 59. (new) The process of claim 34, wherein the lipoprotein material includes cholesterol.

Claim 60. (new) The process of claim 34, wherein the lipoprotein material includes a lipid selected from the group consisting of a triglyceride, a fatty acid and a phospholipid.